No Data
Sector Update: Health Care Stocks Retreating on Thursday
01:53 PM EDT, 09/29/2022 (MT Newswires) -- Health care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking 0.8% and the SPDR Health Care Select Sector ETF (XLV) down 0.9%.
MorphoSys' Monjuvi Shows Long-Term Durable Response In Blood Cancer Settings
MorphoSys AG (NASDAQ:MOR) announced data from the ongoing L-MIND study showing that Monjuvi (tafasitamab-cxix) regime provided long-term efficacy in relapsed or refractory (R/R) diffuse large B-cell l
Fly Intel: Pre-market Movers
Today's Pre-Market Stock Movers: KMX, RAD, BBBY, MTN and More
CarMax's stock fell sharply on Thursday after the used-car dealer reported quarterly profits that were a bit more than half of what Wall Street analysts had expected.
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Gainers PepGen Inc. (NASDAQ:PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial
Fly Intel: After-Hours Movers
MorphoSys Says Monjuvi Immunotherapy Shows Long-Term Efficacy in Lymphoma Patients; Shares Rise After Hours
04:42 PM EDT, 09/28/2022 (MT Newswires) -- MorphoSys (MOR) late Wednesday announced data showing that a combination of its Monjuvi drug candidate and lenalidomide chemotherapy followed by Monjuvi alon
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
Roche is also evaluating gantenerumab in collaboration with MorphoSys AG in autosomal dominant Alzheimer's disease.
MorphoSys Presents New Long-Term Data From L-MIND Suggesting Durable Response To Treatment With Monjuvi For Patients With R/R DLBCL
MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG ((FSE: MOR, NASDAQ:MOR), today announced data from the ongoing L-MIND study showing that Monjuvi (tafasitamab-cxix) plus lenalidomide foll
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session
Gainers Prothena Corporation plc (NASDAQ:PRTA) shares climbed 76.4% to $54.54 after Biogen and Eisai Co. Ltd. announced late Tuesday positive results from a late-stage study of their Alzheimer's trea
Loading...
